Angiotensin-converting enzyme insertion/deletion polymorphism and susceptibility to Henoch–Schönlein purpura: a meta-analysis

Xiaoqing Zhang, Lin Wu, Minglei Chai, Xiaofang Huang, Jiajin Zhu, Shaojun Li, Jun Zhang and Huahong Zhang

Abstract

Objective: Meta-analysis was performed in the current study to evaluate the relationship of the angiotensin-converting enzyme insertion/deletion polymorphism with the risk of the incidence of Henoch–Schönlein purpura.

Methods: The electronic databases, including Embase, PubMed and Google scholar, were systematically retrieved to search for related articles. Meanwhile, statistical analysis was performed using the odds ratio and the corresponding 95% confidence interval.

Results: A total of six articles enrolling 504 patients and 706 healthy controls was enrolled into the current meta-analysis. Results of the meta-analysis suggested that the angiotensin-converting enzyme D allele was markedly correlated with the risk of the incidence of Henoch–Schönlein purpura among the general population (deletion (D) vs. insertion (I): odds ratio (OR) 1.42, 95% confidence interval (CI) 1.05–1.93; DD vs. II: OR 2.23, 95% CI 1.06–4.70; DI vs. II: OR 1.36, 95% CI 1.00–1.85; dominant model: OR 1.56, 95% CI 1.00–2.42; recessive model: OR 1.83, 95% CI 1.06–3.16). Moreover, such a polymorphism was found to correlate with the susceptibility to Henoch–Schönlein purpura when studies were stratified according to the sample size of over 200. In addition, such a polymorphism was recognised to be remarkably associated with the susceptibility to Henoch–Schönlein purpura in the Caucasian population, which was not found in the Asian population.

Conclusions: The results of the current meta-analysis indicate that the angiotensin-converting enzyme D allele might be a risk factor against the risk of Henoch–Schönlein purpura, especially in Caucasians.

Keywords
ACE, I/D polymorphism, angiotensin-converting enzyme

Introduction

Henoch–Schönlein purpura (HSP), the most frequently occurring paediatric systemic vasculitis, has the morbidity of 10–20/100,000. Among them, over 90% of HSP cases are found at the age of onset of less than 10 years. The clinical manifestations of HSP have been extensively recognised, such as palpable non-thrombocytopenic purpura, arthritis and visceral involvement (such as the gastrointestinal tract and the kidney). Generally, HSP is self-limited, which is associated with a favourable long-term prognosis, regardless of the serious involvement of the gastrointestinal tract or the kidney. Currently, the pathogenesis of HSP remains incompletely illustrated. Nonetheless, the interaction between multiple genes and environmental factors is identified to be an important factor in 50% of HSP cases. Importantly, such interaction is proposed to be critical in the development of HSP.

Sodium homeostasis, blood pressure and inflammation in the human body are regulated under the mediation of the renin–angiotensin system (RAS). Typically, HSP is...
induced by the presence of small vasculitis and activation of endothelial cells. In the meantime, RAS has a certain effect on directly regulating the vascular tone and vascular structure; alternatively, such an effect is achieved through different factors, such as endothelin and nitric oxide. On this account, RAS potentially participates in the aetiology of HSP. ACE is a critical circulatory enzyme of RAS, which is extensively expressed in various tissues, such as the kidney, heart, lung, vascular endothelium and testes.

Located on the human chromosome 17q23, the ACE gene has been identified to be associated with plenty of polymorphisms. Typically, the intron 16 insertion/deletion (I/D, rs4646994) polymorphism of ACE is featured by the insertion or deletion of a 287 bp Alu repetitive sequence. Moreover, the homozygous D allele is associated with the highest level of plasma ACE, while the heterozygous allele (ID) is associated with the medium level, and the homozygous I allele is associated with the lowest level. In addition, the ACE I/D polymorphism was reported in a previous meta-analysis to be potentially related to the risk of the disease index. Furthermore, a recent study has identified the highest level of plasma ACE, while the heterozygous allele (ID) is associated with the medium level, and the homozygous I allele is associated with the lowest level. In this study, the meta-analysis was performed according to the accumulating evidence, aiming to investigate the association between the ACE I/D gene polymorphism and the risk of HSP, with the aim of providing a much more reliable finding on the significance of this association.

Subjects and methods

Identification of studies

In this work, the meta-analysis was performed according to the statement guidelines of preferred reporting items for systematic reviews and meta-analysis (PRISMA). The electronic databases, including Google Scholar, PubMed, Embase, CNKI and Wangfang, were systematically retrieved for studies regarding the association of HSP with the ACE I/D polymorphism from database construction to August 2018 without language restrictions, using the search terms of angiotensin-converting enzyme (ACE), Henoch–Schönlein purpura (HSP) and I/D polymorphism. Moreover, the cited references in related studies were also searched to identify the potentially related studies. The latest version of duplicate reports or studies reporting results from the same study population was adopted. In addition, the reference lists of major textbooks, review articles and the included papers were manually retrieved, so as to search for the potentially eligible papers.

Inclusion and exclusion

The study inclusion criteria were as follows: (a) studies that adopted a case–control design; (b) those assessing the relationship between the ACE I/D polymorphism and the risk of HSP; (c) those with the sample size of 40 or greater; and (d) those with sufficient data to calculate the odds ratio (OR) with the corresponding 95% confidence interval (CI). Moreover, the study exclusion criteria are shown below: (a) duplicate reports; (b) comments, reviews and editorials; (c) family-based studies; and (d) those with insufficient genotype data.

Data extraction

Related data, including: (a) authors, (b) publication year, (c) country, (d) ethnicity of the objects of study, (e) sample size, (f) allele and genotype distribution and (g) evidence of Hardy–Weinberg equilibrium (HWE) in controls, were extracted from all eligible studies by two investigators independently, and any disagreement between them was settled by mutual discussion. Moreover, the authors were contacted to collect more information when needed.

Statistical analysis

The strength of the relationship of the ACE I/D polymorphism with susceptibility to HSP was evaluated by ORs and their 95% CIs. In particular, the genetic models below were employed in this meta-analysis, including D versus I, the homozygote comparison (DD vs. II), the heterozygote comparison (DI vs. II), the dominant model (DD + DI vs. II) and the recessive model (II + DI vs. DD). The inconsistency index F was calculated to evaluate the heterogeneity-induced variation; in the case of F greater than 50%, the ORs and 95% CIs were calculated using the random effects model; otherwise, the fixed effects model was utilised. Moreover, a sensitivity test was also carried out, which was achieved through removing one study each time to see its influence on the pooled results. Meanwhile, publication bias was also tested using Begg’s funnel plot and Egger’s funnel plot. A difference of P<0.05 was deemed to be of statistical significance. The STATA software (version 12.0; Stata Corporation, College Station, TX, USA) was used for all statistical analyses.

Results

Study characteristics

A total of 163 potentially related studies was preliminarily retrieved from the electronic databases (Google Scholar,
PubMed, Embase, CNKI and Wangfang), which were then screened by the titles as well as abstract and full-text reading. Finally, a total of six eligible studies was enrolled into the current meta-analysis.9–14 The study selection flow chart is presented in Figure 1. When stratified by ethnicity, two articles were carried out among the Caucasian population and four in the Asian population. Meanwhile, the genotype distribution among the control subjects of the enrolled studies was in agreement with HWE, except for the study by Mohammadian et al.14 Moreover, the enrolled studies were published from 1998 to 2017, and their main characteristics are displayed in Table 1.

**Main results**

Table 2 displays the major findings from the current meta-analysis on the association of the ACE I/D polymorphism with susceptibility to HSP. Data from all the enrolled studies were pooled, and the results suggested that the ACE D allele is markedly correlated with the susceptibility to HSP (D vs. I: OR 1.42, 95% CI 1.05–1.93; Figure 2: DD vs. II: OR 2.23, 95% CI 1.06–4.70; DI vs. II: OR 1.36, 95% CI 1.00–1.85; dominant model: OR 1.56, 95% CI 1.00–2.42; recessive model: OR 1.83, 95% CI 1.06–3.16). Besides, studies were further divided into two groups according to the sample size of over 200 or 200 or less for subgroup analysis, and the results indicated that the ACE I/D polymorphism is remarkably correlated with the susceptibility to HSP in the sample size of over 200 subgroup (D vs. I: OR 1.69, 95% CI 1.41–2.02; DD vs. II: OR 4.04, 95% CI 2.57–6.36; DI vs. II: OR 1.62, 95% CI 1.15–2.29; dominant model: OR 2.11, 95% CI 1.52–2.92; recessive model: OR 2.56, 95% CI 1.44–4.52), which could not be observed in that of the 200 or less subgroup (D vs. I: OR 0.83, 95% CI 0.57–1.21; DD vs. II: OR 0.67, 95% CI 0.33–1.36; DI vs. II: OR 0.63, 95% CI 0.31–1.28; dominant model: OR 0.65, 95% CI 0.34–1.23; recessive model: OR 0.92, 95% CI 0.54–1.58). In addition, studies were also stratified according to ethnicity for subgroup analysis, and the results found a significant correlation of the ACE I/D polymorphism with the susceptibility to HSP in the Caucasian population (D vs. I: OR 1.63, 95% CI 1.07–2.49; DD vs. II: OR 3.60, 95% CI 1.89–6.84; DI vs. II: OR 2.04, 95% CI 1.18–3.53; dominant model: OR 2.48, 95% CI 1.46–4.23; recessive model: OR 3.60, 95% CI 1.89–6.84).

### Table 1. Characteristics of the included studies for meta-analysis.

| Study included | Year | Area | Race | Cases/controls | Allele for cases | Allele for controls | Genotypes for cases | Genotypes for controls | HWE test |
|---------------|------|------|------|----------------|------------------|---------------------|---------------------|-----------------------|----------|
| Yoshioka      | 1998 | Japan | Asians | 40/79 | 49 31 | 101 57 | 17 15 8 | 33 35 11 | 0.73 |
| Zhou          | 2004 | China | Asians | 103/100 | 92 114 | 51 149 | 30 32 41 | 6 39 55 | 0.79 |
| Ozkaya        | 2006 | Turkey | Caucasians | 114/164 | 124 104 | 155 173 | 18 88 8 | 19 117 28 | 0.00 |
| Liu           | 2010 | China | Asians | 61/217 | 121 159 | 144 290 | 11 33 17 | 21 102 94 | 0.38 |
| Nalbantoglu   | 2013 | Turkey | Caucasians | 139/72 | 180 98 | 68 76 | 61 58 20 | 16 36 20 | 0.98 |
| Mohammadian   | 2017 | Iran  | Asians | 47/74 | 50 44 | 88 60 | 17 16 14 | 30 28 16 | 0.06 |

HWE: Hardy–Weinberg equilibrium.
recessive model: OR 1.05, 95% CI 1.29–3.27), but not in the Asian population (D vs. I: OR 1.30, 95% CI 0.81–2.07; DD vs. II: OR 1.75, 95% CI 0.58–5.27; DI vs. II: OR 1.12, 95% CI 0.77–1.62; dominant model: OR 1.22, 95% CI 0.68–2.19; recessive model: OR 1.78, 95% CI 0.76–4.16).

**Heterogeneity analysis and publication bias**

Sensitivity analysis was carried out by eliminating one non-HWE study each time to observe the influence on the final result. In particular, an unchanged final result suggested that the meta-analysis result was statistically significant (Table 2). On the other hand, the publication bias among the enrolled studies was assessed through Begg’s funnel plot and Egger’s funnel plot, and no evidence of obvious asymmetry was observed from the shape of the funnel plot, revealing no obvious evidence of publication bias for the ACE I/D polymorphism (Figures 3 and 4).

**Discussion**

HSP, the most frequently occurring vasculitis syndrome, is associated with the major clinical manifestations of skin purpura, arthritis as well as gastrointestinal tract disease. The ACE I/D polymorphism is correlated with the ACE
contents in the circulation and cells, which may be potentially involved in the pathogenesis of HSP. It has been widely examined in a number of epidemiological studies. Nonetheless, the results from different studies remain a source of controversy. Thus, intensively understanding such a problem is of great clinical significance, which may potentially suggest that the ACE I/D polymorphism can predict the risk of HSP. On this account, the current meta-analysis was carried out to evaluate better the association of the ACE I/D polymorphism with susceptibility to HSP.

A total of six eligible case–control studies involving 504 patients and 706 control subjects were enrolled into the current meta-analysis to assess systemically the relationship of the ACE I/D polymorphism with susceptibility to HSP. The pooled findings of this meta-analysis indicated that the ACE D allele is associated with increased HSP risk. In the stratified analysis by sample size, pooled results showed a significant association with a sample size greater than 200 but not with a sample size of 200 or less, indicating there was no small-study bias in this meta-analysis. In term of stratified analyses by race, our findings indicate that the ACE I/D polymorphism had a significant association with HSP risk in Caucasians, but not in Asians. Such heterogeneities might result from the differences in genetic background and environmental exposure. Moreover, the deviation of allelic distributions from HWE may contribute to between-study heterogeneity, the subgroup analysis by limiting this meta-analysis to those papers that are consistent with HWE revealed that our data were believable.

The precise underlying mechanism of HSP has not yet been fully illustrated. It is widely accepted that RAS plays a key role in the development of HSP. Typically, ACE is important in the conversion of RAS and angiotensin II, which can enhance the content of vascular smooth muscle cells and influences the proliferation of smooth muscle cells, adhesion and aggregation of monocytes and platelets. The ACE I/D polymorphism is located in an intron of the ACE gene, and the ACE I/D polymorphism accounts for approximately one-half of the variance in ACE plasma levels. Moreover, the homozygous D allele is associated with the highest level of plasma ACE. Taken together, our findings suggesting that ACE may be a risk factor for the development of HSP are biologically plausible. A previous meta-analysis showed that the M allele of the angiotensinogen (AGT) M235T polymorphism in the RAS gene was associated with the risk of HSP. Gene–gene interactions are very important for the pathogenesis of HSP, and single genetic changes may present only a modest effect. Because the complete genotype information was unavailable, we could not perform gene–gene interaction analysis.

There are some limitations in the current study. First, only two out of the eligible studies were performed among Caucasians, which could not provide enough statistical power to detect the possible effects of the ACE I/D polymorphism in Caucasians. Second, only published literature was included in this study, while some potentially relevant studies that were not published were excluded, probably resulting in publication bias. Third, the influence of interactions between genes, as well as environmental factors, had not been examined in the current meta-analysis.

In conclusion, the present meta-analysis suggests that the ACE D allele might increase the risk of HSP, especially in the Caucasian population. In addition, understanding the combination of genetic factors together with environmental exposures will increase our understanding of the aetiology of HSP.

Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD
Xiaoqing Zhang https://orcid.org/0000-0001-8830-8779
References
1. Gardner-Medwin JM, Dolezalova P, Cummins C, et al. Incidence of Henoch–Schonlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. *Lancet* 2002; 360: 1197–1202.
2. Brogan PA. What’s new in the aetiopathogenesis of vasculitis? *Pediatr Nephrol* 2007; 22: 1083–1094.
3. Raizada V, Skipper B, Luo W, et al. Intracardiac and intrarenal renin–angiotensin systems: mechanisms of cardiovascular and renal effects. *J Invest Med* 2007; 55: 341–359.
4. Fuentes Y, Hernández AM, García-Roca P, et al. Urinary MCP-1/creatinine in Henoch–Schonlein purpura and its relationship with nephritis. *Pediatr Nephrol* 2014; 29: 1047–1052.
5. Anderson PW, Do YS and Hsueh WA. Angiotensin II causes mesangial cell hypertrophy. *Hypertension* 1993; 21: 29–35.
6. Castellon R and Hamdi HK. Demystifying the ACE polymorphism: from genetics to biology. *Curr Pharm Des* 2007; 13: 1191–1198.
7. Rigat B, Hubert C, Alhenc-Gelas F, et al. An insertion/deletion polymorphism in the angiotensin I converting enzyme gene accounting for half the variance of serum enzyme levels. *J Clin Invest* 1990; 86: 1343–1346.
8. Pan Y and Lu H. Angiotensin-converting enzyme insertion/deletion polymorphism and susceptibility to Kawasaki disease: a meta-analysis. *Afr Health Sci* 2017; 17: 991–999.
9. Yoshioka T, Xu YX, Yoshida H, et al. Deletion polymorphism of the angiotensin converting enzyme gene predicts persistent proteinuria in Henoch–Schönlein purpura nephritis. *Arch Dis Child* 1998; 79: 394–399.
10. Zhou J, Tian X and Xu Q. Angiotensin-converting enzyme gene insertion/deletion polymorphism in children with Henoch–Schönlein purpura nephritis. *J Huazhong Univ Sci Technolog Med Sci* 2004; 24: 158–161.
11. Ozkaya O, Söylemezoğlu O, Gönen S, et al. Renin–angiotensin system gene polymorphisms: association with susceptibility to Henoch–Schönlein purpura and renal involvement. *Clin Rheumatol* 2006; 25: 861–865.
12. Liu D, Lu F, Zhai S, et al. Renin–angiotensin system gene polymorphisms in children with Henoch–Schönlein purpura in West China. *J Renin Angiotensin Aldosterone Syst* 2010; 11: 248–255.
13. Nalbantoglu S, Tabel Y, Mir S, et al. Association between RAS gene polymorphisms (ACE I/D, AGT M235T) and Henoch–Schönlein purpura in a Turkish population. *Dis Markers* 2013; 34: 23–32.
14. Mohammadian T, Bonyadi M, Nabat E, et al. Association of ACE, VEGF and CCL2 gene polymorphisms with Henoch–Schönlein purpura and an evaluation of the possible interaction effects of these loci in HSP patients. *Adv Clin Exp Med* 2017; 26: 661–664.
15. Zaffanello M and Fanos V. Treatment-based literature of Henoch–Schönlein purpura nephritis in childhood. *Pediatr Nephrol* 2009; 24: 1901–1911.
16. Rigat B, Hubert C, Alhenc-Gelas F, et al. An insertion/deletion polymorphism in the angiotensin I converting enzyme gene accounting for half the variance of serum enzyme levels. *J Clin Invest* 1990; 86: 1343–1346.
17. Mao S and Huang S. Association of AGT M235T gene polymorphism with HSP/HSPN risk. *Ren Fail* 2015; 37: 16–21.